Literature DB >> 9884335

Expression of the AT2 receptor developmentally programs extracellular signal-regulated kinase activity and influences fetal vascular growth.

M Akishita1, M Ito, J Y Lehtonen, L Daviet, V J Dzau, M Horiuchi.   

Abstract

Angiotensin II type 2 (AT2) receptor is abundantly expressed in vascular smooth muscle cells (VSMC) of the fetal vasculature during late gestation (embryonic day 15-20), during which the blood vessels undergo remodeling. To examine directly the influence of AT2 receptor expression in the developmental biology of VSMC, we studied cultures of VSMC from fetal and postnatal wild-type (Agtr2(+)) and AT2 receptor null (Agtr2(-)) mice. Consistent with in vivo data, AT2 receptor binding in cultured Agtr2(+) VSMC increased by age, peaking at embryonic day 20, and decreased dramatically after birth. Angiotensin II-induced growth in Agtr2(+) VSMC (embryonic day 20) was increased by the AT2 receptor blocker PD123319, indicating that the AT2 receptors are functional and exert an antigrowth effect in Agtr2(+) VSMC. Growth of VSMC in response to serum decreased age dependently and was higher in Agtr2(-) than in Agtr2(+), inversely correlating with AT2 receptor expression. However, serum-induced growth in Agtr2(+) and Agtr2(-) VSMC and the exaggerated Agtr2(-) VSMC growth was maintained even in the presence of PD123319 or losartan, an AT1 receptor blocker. Moreover, Agtr2(-) VSMC showed greater growth responses to platelet-derived growth factor and basic fibroblast growth factor, indicating that Agtr2(-) cells exhibit a generalized exaggerated growth phenotype. We studied the mechanism responsible for this phenotype and observed that extracellular signal-regulated kinase (ERK) activity was higher in Agtr2(-) VSMC at baseline and also in response to serum. ERK kinase inhibitor PD98059 inhibited both growth and ERK phosphorylation dose-dependently, while the regression lines between growth and ERK phosphorylation were identical in Agtr2(+) and Agtr2(-) VSMC, suggesting that increased ERK activity in Agtr2(-) VSMC is pivotal in the growth enhancement. Furthermore, the difference in ERK phosphorylation between Agtr2(+) and Agtr2(-) was abolished by vanadate but not by okadaic acid, implicating tyrosine phosphatase in the difference in ERK activity. These results suggest that the AT2 receptor expression during the fetal vasculogenesis influences the growth phenotype of VSMC via the modulation of ERK cascade.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9884335      PMCID: PMC407869          DOI: 10.1172/JCI5182

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  Mitogen-activated protein kinase activation: an alternate signaling pathway for sustained vascular smooth muscle contraction.

Authors:  A M Epstein; D Throckmorton; C M Brophy
Journal:  J Vasc Surg       Date:  1997-08       Impact factor: 4.268

2.  Differential expression of MAM-subfamily protein tyrosine phosphatases during mouse development.

Authors:  M Fuchs; H Wang; T Ciossek; Z Chen; A Ullrich
Journal:  Mech Dev       Date:  1998-01       Impact factor: 1.882

3.  Activation of mitogen-activated protein kinases (ERK/JNK) and AP-1 transcription factor in rat carotid arteries after balloon injury.

Authors:  Y Hu; L Cheng; B W Hochleitner; Q Xu
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-11       Impact factor: 8.311

Review 4.  Growth factors and mitogen-activated protein kinases.

Authors:  T Force; J V Bonventre
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

5.  Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects.

Authors:  H Masaki; T Kurihara; A Yamaki; N Inomata; Y Nozawa; Y Mori; S Murasawa; K Kizima; K Maruyama; M Horiuchi; V J Dzau; H Takahashi; T Iwasaka; M Inada; H Matsubara
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

6.  Differential distribution of angiotensin AT2 receptors in the normal and failing human heart.

Authors:  J Wharton; K Morgan; R A Rutherford; J D Catravas; A Chester; B F Whitehead; M R De Leval; M H Yacoub; J M Polak
Journal:  J Pharmacol Exp Ther       Date:  1998-01       Impact factor: 4.030

7.  Age influences the replicative activity and the differentiation features of cultured rat aortic smooth muscle cell populations and clones.

Authors:  M L Bochaton-Piallat; F Gabbiani; P Ropraz; G Gabbiani
Journal:  Arterioscler Thromb       Date:  1993-10

8.  Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors.

Authors:  M Mukoyama; M Nakajima; M Horiuchi; H Sasamura; R E Pratt; V J Dzau
Journal:  J Biol Chem       Date:  1993-11-25       Impact factor: 5.157

9.  Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: an in vitro gene transfer study.

Authors:  T Yamada; M Akishita; M J Pollman; G H Gibbons; V J Dzau; M Horiuchi
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

10.  Rat carotid neointimal smooth muscle cells reexpress a developmentally regulated mRNA phenotype during repair of arterial injury.

Authors:  M W Majesky; C M Giachelli; M A Reidy; S M Schwartz
Journal:  Circ Res       Date:  1992-10       Impact factor: 17.367

View more
  25 in total

Review 1.  Angiotensin AT2 receptor ligands: do they have potential as future treatments for neurological disease?

Authors:  Philip Rosenstiel; Stefan Gallinat; Alexander Arlt; Thomas Unger; Jobst Sievers; Ralph Lucius
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Dissection of the c-Kit signaling pathway in mouse primordial germ cells by retroviral-mediated gene transfer.

Authors:  Maria P De Miguel; Linzhao Cheng; Eric C Holland; Mark J Federspiel; Peter J Donovan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-24       Impact factor: 11.205

Review 3.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

Review 4.  Transforming growth factor beta signaling in adult cardiovascular diseases and repair.

Authors:  Thomas Doetschman; Joey V Barnett; Raymond B Runyan; Todd D Camenisch; Ronald L Heimark; Henk L Granzier; Simon J Conway; Mohamad Azhar
Journal:  Cell Tissue Res       Date:  2011-09-28       Impact factor: 5.249

Review 5.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

6.  A role for the renin-angiotensin system in hematopoiesis.

Authors:  Tea Soon Park; Elias T Zambidis
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

7.  High glucose up-regulates angiotensin II subtype 2 receptors via interferon regulatory factor-1 in proximal tubule epithelial cells.

Authors:  Quaisar Ali; Rifat Sabuhi; Tahir Hussain
Journal:  Mol Cell Biochem       Date:  2010-07-02       Impact factor: 3.396

8.  Angiotensin AT2 receptor agonist prevents salt-sensitive hypertension in obese Zucker rats.

Authors:  Quaisar Ali; Sanket Patel; Tahir Hussain
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-08

9.  Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin.

Authors:  Stella Sarlos; Bishoy Rizkalla; Christina J Moravski; Zemin Cao; Mark E Cooper; Jennifer L Wilkinson-Berka
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

10.  Posttranscriptional regulation of angiotensin II type 1 receptor expression by glyceraldehyde 3-phosphate dehydrogenase.

Authors:  Michael Backlund; Kirsi Paukku; Laurent Daviet; Rudolf A De Boer; Erkka Valo; Sampsa Hautaniemi; Nisse Kalkkinen; Afshin Ehsan; Kimmo K Kontula; Jukka Y A Lehtonen
Journal:  Nucleic Acids Res       Date:  2009-02-26       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.